Generated by AI
Serina Therapeutics Inc. is a clinical-stage biotechnology company focused on developing polymer-enabled therapeutics for neurological diseases and other serious conditions. The company’s core work centers on its proprietary POZ Platform, a drug-delivery technology designed to improve how medicines are loaded, released, and administered, with applications across small molecules, RNA-based therapies, and antibody-drug conjugates. Serina Therapeutics Inc. is advancing a pipeline of wholly owned product candidates aimed primarily at central nervous system disorders, including Parkinson’s disease, along with programs in pain and other therapeutic areas. Its current business is centered on research, preclinical development, and clinical evaluation of drug candidates built around its platform technology. Based in Huntsville, Alabama, Serina Therapeutics Inc. plays a specialized role in the biotechnology market by combining materials science with drug development to address treatment challenges in difficult-to-deliver therapies.
Website601 Genome Way
Huntsville, AL, 35806
United States
The latest articles about SER.
Tipranks Press Release.
Featuring Serina Therapeutics’ CEO - Thursday, September 24, 202610M people in the world currently living with Parkinson’s diseasewith no major cl...
Summary of May 21's posts. Generated by AI.
Summary of May 21's posts. Generated by AI.
No summary yet.
Summary of May 11's posts. Generated by AI.
Investors talking about SER also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.